CNP-106

Phase 2Small molecule

CCOUR Pharmaceutical Development Company, Inc.

CNP-106 is one of 25 small molecule programs targeting Myasthenia Gravis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myasthenia GravisRecruiting

Myasthenia GravisPhase 2

Recruiting

Competition

Competitive Landscape

26 competitors in Myasthenia Gravis

#DrugCompanyPhaseTrials

Ultomiris

AstraZeneca

Approved

4 2

Vyvgart

Argenx

Approved

10 3

Rysodeg

UCB

Approved

2 4

Rituxan

Roche

Phase 3

7 5

Rayos

RRoxane Laboratories

Approved

—6

Proair HFA

GGlaxo Dba Glaxosmithkline

Blincyto

2 8

Actemra

Roche

Phase 3

2 9

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 3

1 10

Fabhalta

Johnson & Johnson

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Myasthenia Gravis1 trial

Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

Recruiting·CCOUR Pharmaceutical Development Company, Inc.·Phase 1/2·NCT06106672·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CNP-106. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CNP-106 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CNP-106. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — COUR Pharmaceutical Development Company, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCOUR Pharmaceutical Development Company, Inc.

CNP-106

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Myasthenia Gravis1 trial

References

Drug Info

Quick Facts

Related News